Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

医学 达沙替尼 伊马替尼 淋巴细胞白血病 甲磺酸伊马替尼 急性淋巴细胞白血病 随机对照试验 肿瘤科 内科学 随机化 儿科 费城染色体 临床试验 白血病 髓系白血病 染色体易位 化学 基因 生物化学
作者
Shuhong Shen,Xiaojuan Chen,Jiaoyang Cai,Jie Yu,Ju Gao,Shaoyan Hu,Xiaowen Zhai,Changda Liang,Xiuli Ju,Hua Jiang,Runming Jin,Xuedong Wu,Ningling Wang,Xin Tian,Kaili Pan,Hui Jiang,Lirong Sun,Yongjun Fang,Chi Kong Li,Qun Hu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (3): 358-358 被引量:251
标识
DOI:10.1001/jamaoncol.2019.5868
摘要

Importance: A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Objective: To determine whether dasatinib given at a daily dosage of 80 mg/m2 is more effective than imatinib mesylate at a daily dosage of 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation. Design, Setting, and Participants: This open-label, phase 3 randomized clinical trial was conducted at 20 hospitals in China. Enrollment occurred from January 1, 2015, through September 18, 2018, and randomization was stopped on October 4, 2018, when the early stopping criterion of the trial was met. Patients aged 0 to 18 years were recruited. Of the 225 patients with the diagnosis, 35 declined participation and 1 died before treatment, leaving 189 patients available for analysis. Data were analyzed from January 1 through August 4, 2019. Interventions: Patients were randomized to receive daily dasatinib (n = 92) or imatinib (n = 97) continuously for the entire duration of ALL therapy from the time of diagnosis made during remission induction to the end of continuation therapy. Main Outcomes and Measures: The primary outcome was event-free survival, analyzed based on intention to treat. The secondary outcomes were relapse, death due to toxic effects, and overall survival. Results: Among the 189 participants (136 male [72.0%]; median age, 7.8 [interquartile range (IQR), 5.2-11.3] years) and a median follow-up of 26.4 (IQR, 16.3-34.1) months, the 4-year event-free survival and overall survival rates were 71.0% (95% CI, 56.2%-89.6%) and 88.4% (95% CI, 81.3%-96.1%), respectively, in the dasatinib group and 48.9% (95% CI, 32.0%-74.5%; P = .005, log-rank test) and 69.2% (95% CI, 55.6%-86.2%; P = .04, log-rank test), respectively, in the imatinib group. The 4-year cumulative risk of any relapse was 19.8% (95% CI, 4.2%-35.4%) in the dasatinib group and 34.4% (95% CI, 15.6%-53.2%) in the imatinib group (P = .01, Gray test), whereas the 4-year cumulative risk of an isolated central nervous system relapse was 2.7% (95% CI, 0.0%-8.1%) in the dasatinib group and 8.4% (95% CI, 1.2%-15.6%) in the imatinib group (P = .06, Gray test). There were no significant differences in the frequency of severe toxic effects between the 2 treatment groups. Conclusions and Relevance: Intensive chemotherapy including dasatinib at a dosage of 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared with imatinib mesylate at a dosage of 300 mg/m2 per day and provided excellent control of central nervous system leukemia without the use of prophylactic cranial irradiation. Trial Registration: Chinese Clinical Trial Registry: ChiCTR-IPR-14005706.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
有个女孩叫阿娇完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
顺利的蛋挞完成签到,获得积分10
2秒前
3秒前
3秒前
东门吹雪完成签到,获得积分10
3秒前
regina完成签到,获得积分20
5秒前
5秒前
余香的应助被jay8696采纳,获得10
5秒前
7秒前
Ting发布了新的文献求助10
7秒前
7秒前
盈虚者发布了新的文献求助10
7秒前
汉堡包的应助被醒醒采纳,获得10
7秒前
sunsuan发布了新的文献求助10
7秒前
lx20021111完成签到,获得积分10
8秒前
蓝月发布了新的文献求助30
8秒前
于66发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
zhy1103完成签到 ,获得积分10
9秒前
10秒前
10秒前
余香的应助被追寻的沛白采纳,获得10
10秒前
情怀的应助被syy采纳,获得10
11秒前
12秒前
11111发布了新的文献求助10
12秒前
科研通AI6.4的应助被夏佳泽采纳,获得10
13秒前
L晨晨完成签到 ,获得积分10
13秒前
Firewoods发布了新的文献求助20
13秒前
bitter完成签到 ,获得积分10
14秒前
14秒前
15秒前
斯文败类的应助被Poseidon采纳,获得10
15秒前
15秒前
www完成签到,获得积分10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005